Journal: JAMA Network Open

Article Title: Second-Line Treatment Strategies for Right-Sided, RAS/RAF Wild-Type Colorectal Cancer

doi: 10.1001/jamanetworkopen.2025.15087

Figure Lengend Snippet: Estimated survival functions were generated independently for each of 25 imputations, with the mean subsequently calculated at each time interval to generate the estimated survival function after multiple imputation. Because the plot represents means of estimated survival functions and not directly observed data, the number at risk at each time are not provided. Estimated median survival was 15.6 months (95% CI, 12.5-17.1 months) in unadjusted and 15.3 months (95% CI, 12.5-17.1 months) in adjusted analysis for patients treated with anti–vascular endothelial growth factor (VEGF) therapy and 12.0 months (95% CI, 9.8-15.3 months) in unadjusted and 12.1 months (95% CI, 10.5-15.3 months) in adjusted analysis for patients treated with anti–epidermal growth factor receptor (EGFR) therapy. IPTW indicates stabilized inverse probability of treatment weights.

Article Snippet: After MICE, we used Cox proportional hazards modeling with stabilized inverse probability of treatment weighting (IPTW) to assess the adjusted association of anti-EGFR vs anti-VEGF–containing treatment with OS using Stata/SE statistical software version 18.5 (StataCorp) (eMethods, eFigure 1, and eFigure 2 in ).

Techniques: Generated